Insiders · ADAP

ADAP insider transactions

Adaptimmune Therapeutics plc (ADAP) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

ADAP insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Adaptimmune Therapeutics plc, latest first. Follow anyone to get their next filing.

• Christopher James HillChief Financial Officer, since September 2025
• Gavin WoodChief Financial Officer+$11.3K-$950
• William C Bertrand JRChief Operating Officer-$139K
• Ali BehbahaniDirector-$229K
• New Enterprise Associates 14, L.P.Insider
• EcoR1 Capital, LLC10% owner, since March 2024-$6.89M
• Joanna Elizabeth BrewerChief Scientific Officer, since May 2022
• John LungerChief Patient Supply Officer-$146K
• Cintia PiccinaChief Commercial Officer, since January 2022-$89.8K
• Elliot NorryChief Medical Officer-$104K
• Adrian RawcliffeChief Executive Officer, Director-$402K
• David M MottDirector
• Garry E MenzelDirector, since June 2023-$43.4K
• Kristen HegeDirector, since November 2023
• Priti HegdeDirector, since June 2023
• John FureyDirector
• Lawrence M AllevaDirector+$9,954
• Andrew R AllenDirector, since June 2023
• Helen Katrina Tayton-MartinChief Business & Strgy Officer
• Charles Elliott SigalDirector
• Tal Zvi ZaksDirector
• James NobleDirector
• Barbara Gayle DuncanDirector

Recent Form 3, 4, and 5 filings for ADAP

• 396d
  SEC Form 3 filed by new insider Hill Christopher James

  3 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 431d
  Chief Financial Officer Wood Gavin sold $950 worth of Ordinary Shares with a nominal value of GBP0.001 per share (96,000 units at $0.01), closing all direct ownership in the company (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 436d
  Chief Operating Officer Bertrand William C Jr sold $2,091 worth of Ordinary Shares with a nominal value of GBP0.001 per share (207,000 units at $0.01), decreasing direct ownership by 17% to 986,352 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 446d
  Director Behbahani Ali sold $229,172 worth of Ordinary Shares with a nominal value of 0.001 GBP per share (19,500,000 units at $0.01) (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 466d
  Large owner Ecor1 Capital, Llc sold $6,890,236 worth of Ordinary Shares (64,052,538 units at $0.11) (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 626d
  SEC Form 4 filed by Chief Operating Officer Bertrand William C Jr

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 626d
  SEC Form 4 filed by Chief Scientific Officer Brewer Joanna Elizabeth

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 626d
  SEC Form 4 filed by Chief Patient Supply Officer Lunger John

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 626d
  SEC Form 4 filed by Chief Commercial Officer Piccina Cintia

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 626d
  SEC Form 4 filed by Chief Medical Officer Norry Elliot

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 626d
  SEC Form 4 filed by Chief Executive Officer Rawcliffe Adrian

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 660d
  Chief Medical Officer Norry Elliot sold $3,243 worth of American Depositary Shares representing Ordinary Shares (5,584 units at $0.58), decreasing direct ownership by 43% to 7,510 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 660d
  Chief Patient Supply Officer Lunger John sold $3,243 worth of American Depositary Shares representing Ordinary Shares (5,584 units at $0.58), decreasing direct ownership by 43% to 7,510 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 660d
  Chief Operating Officer Bertrand William C Jr sold $3,243 worth of American Depositary Shares representing Ordinary Shares (5,584 units at $0.58), decreasing direct ownership by 43% to 7,510 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 660d
  Chief Executive Officer Rawcliffe Adrian sold $17,773 worth of American Depositary Shares representing Ordinary Shares (30,601 units at $0.58), decreasing direct ownership by 41% to 44,327 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 662d
  Chief Executive Officer Rawcliffe Adrian sold $34,639 worth of American Depositary Shares representing Ordinary Shares (59,569 units at $0.58), increasing direct ownership by 37% to 41,582 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 662d
  Chief Commercial Officer Piccina Cintia sold $7,467 worth of American Depositary Shares representing Ordinary Shares (12,991 units at $0.57), decreasing direct ownership by 41% to 18,421 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 662d
  Chief Medical Officer Norry Elliot sold $12,920 worth of American Depositary Shares representing Ordinary Shares (22,195 units at $0.58), increasing direct ownership by 36% to 13,756 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 662d
  Chief Patient Supply Officer Lunger John sold $11,360 worth of American Depositary Shares representing Ordinary Shares (19,542 units at $0.58), increasing direct ownership by 36% to 13,756 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 662d
  Chief Operating Officer Bertrand William C Jr sold $11,360 worth of American Depositary Shares representing Ordinary Shares (19,542 units at $0.58), increasing direct ownership by 36% to 13,756 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 860d
  SEC Form 4 filed by Director Behbahani Ali

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 860d
  SEC Form 4 filed by Director Mott David M

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 860d
  SEC Form 4 filed by Director Menzel Garry E

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 860d
  SEC Form 4 filed by Director Hege Kristen

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 860d
  SEC Form 4 filed by Director Hegde Priti

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 860d
  SEC Form 4 filed by Director Furey John

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 860d
  SEC Form 4 filed by Director Alleva Lawrence M

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 860d
  SEC Form 4 filed by Director Allen Andrew R

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 873d
  Chief Commercial Officer Piccina Cintia sold $22,814 worth of American Depositary Shares representing Ordinary Shares (24,531 units at $0.93), decreasing direct ownership by 39% to 38,293 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 958d
  New insider Ecor1 Capital, Llc claimed ownership of 164,424,420 units of Ordinary Shares (SEC Form 3)

  3 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 965d
  SEC Form 4 filed by Piccina Cintia

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  Rawcliffe Adrian sold $27,594 worth of American Depositary Shares representing Ordinary Shares (39,384 units at $0.70), increasing direct ownership by 92% to 44,848 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  Norry Elliot sold $14,106 worth of American Depositary Shares representing Ordinary Shares (20,563 units at $0.69), increasing direct ownership by 241% to 19,257 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  Lunger John sold $15,889 worth of American Depositary Shares representing Ordinary Shares (22,795 units at $0.70), increasing direct ownership by 62% to 19,015 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  Bertrand William C Jr sold $16,423 worth of American Depositary Shares representing Ordinary Shares (23,589 units at $0.70), increasing direct ownership by 73% to 20,201 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  SEC Form 4 filed by Behbahani Ali

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  SEC Form 4 filed by Bertrand William C Jr

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  SEC Form 4 filed by Hege Kristen

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  SEC Form 4 filed by Lunger John

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  SEC Form 4 filed by Brewer Joanna Elizabeth

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  SEC Form 4 filed by Tayton-Martin Helen Katrina

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  SEC Form 4 filed by Wood Gavin

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  SEC Form 4 filed by Norry Elliot

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1026d
  SEC Form 4 filed by Rawcliffe Adrian

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1031d
  Bertrand William C Jr sold $7,813 worth of American Depositary Shares representing Ordinary Shares (9,229 units at $0.85), decreasing direct ownership by 22% to 7,874 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1031d
  Norry Elliot sold $10,015 worth of American Depositary Shares representing Ordinary Shares (11,808 units at $0.85), increasing direct ownership by 17% to 11,841 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1031d
  Rawcliffe Adrian sold $24,734 worth of American Depositary Shares representing Ordinary Shares (29,202 units at $0.85), decreasing direct ownership by 13% to 26,388 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1031d
  Lunger John sold $7,813 worth of American Depositary Shares representing Ordinary Shares (9,229 units at $0.85), decreasing direct ownership by 22% to 7,874 units (SEC Form 4)

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1103d
  SEC Form 3 filed by new insider Hege Kristen

  3 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1164d
  SEC Form 4: Rawcliffe Adrian sold $1,874 worth of American Depositary Shares representing Ordinary Shares (2,403 units at $0.78), decreasing direct ownership by 41% to 3,449 units

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1195d
  SEC Form 4: Lunger John sold $2,804 worth of American Depositary Shares representing Ordinary Shares (3,096 units at $0.91), decreasing direct ownership by 40% to 4,718 units

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1217d
  SEC Form 4 filed by Menzel Garry E

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1222d
  SEC Form 4 filed by Hegde Priti

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1222d
  SEC Form 4 filed by Allen Andrew R

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1222d
  SEC Form 4 filed by Menzel Garry E

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1224d
  SEC Form 4 filed by Behbahani Ali

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1224d
  SEC Form 4 filed by Hegde Priti

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1224d
  SEC Form 4 filed by Furey John

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1224d
  SEC Form 4 filed by Menzel Garry E

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
• 1224d
  SEC Form 4 filed by Sigal Charles Elliott

  4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)